Omar Nadeem, Md

This phase 2 trial tests whether a combination of four drugs—daratumumab, bortezomib, lenalidomide, and dexamethasone—can stop high-risk smoldering multiple myeloma from progressing to active multiple myeloma. Participants must be 18 or older and meet specific high-risk criteria.…

This study tests a combination of three oral drugs—ixazomib, pomalidomide, and dexamethasone—given twice weekly to people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to find a safe and effective dose that controls the cancer. The tri…